Efficacy studies showed that a TSGs-containing (p53, Fhit, Fus1, TSG101, or IL-24) nanocarrier, when administered intratumorally, produced significant growth inhibition compared to tumor growth inhibition produced by nanocarrier treatment containing control plasmid DNA [44, 46, 47]. This evidence concerns the gene IL24 and neoplasm.